Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,180 across all filing types
Latest filing 2023-04-25 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Board Meeting — Financial Results/Dividend/Other business matters
Regulatory Filings Classification · 95% confidence The document is a short notice dated April 25, 2023, addressed to stock exchanges, informing about a forthcoming Board of Directors meeting scheduled for May 9, 2023. The purpose of the meeting includes considering and taking on record the audited financial results for the quarter and year ended March 31, 2023, and recommending dividends. The document is brief (1598 characters) and serves as an announcement of an upcoming event rather than containing any financial results or detailed reports itself. It does not contain actual financial data or analysis, nor is it a transcript or detailed presentation. It is clearly a notification about a board meeting to consider financial results, which fits the category of Regulatory Filings (RNS) as a general regulatory announcement and does not qualify as an Interim Report or Annual Report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-04-25 English
LUPIN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/05/2023 ,inter alia, to consider and approve the audited financial results of the ....
Regulatory Filings Classification · 95% confidence The document is a notice dated April 25, 2023, addressed to stock exchanges, informing about a forthcoming Board of Directors meeting scheduled for May 9, 2023. The purpose of the meeting includes considering and taking on record the audited financial results for the quarter and year ended March 31, 2023, and recommending a dividend if any. The document is short (1606 characters) and serves as an announcement of an upcoming event rather than containing any financial data or results itself. It does not contain the actual financial statements or detailed report but merely informs stakeholders about the meeting where such reports will be discussed. Therefore, this document is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not fit into other specific categories like Annual Report or Earnings Release.
2023-04-25 English
Lupin Diagnostics Launches Regional Reference Laboratory in Bengaluru, Strengthening Presence in South India.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a new Regional Reference Laboratory by Lupin Diagnostics. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI Listing Obligations and Disclosure Requirements, which typically covers material events or information about the company. The content focuses on business expansion and operational updates rather than financial results, management changes, or regulatory filings. It does not contain financial statements or detailed financial analysis, nor does it announce voting results, dividends, or share transactions. The document is not a report but an announcement of a corporate event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-04-12 English
Press Release
Capital/Financing Update Classification · 90% confidence The document is a press release announcing the launch of a new Regional Reference Laboratory by Lupin Diagnostics. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI Listing Obligations and Disclosure Requirements, which typically covers material events or corporate announcements. The content focuses on business expansion and operational updates rather than financial results, management changes, or regulatory filings. It does not contain financial statements, earnings data, or detailed management discussion. The document is approximately 6964 characters, which is relatively short and consistent with a press release or corporate announcement rather than a full report. Therefore, it fits best under the category of Capital/Financing Update (CAP) as it relates to business expansion and operational growth announcements disclosed to the market under listing regulations.
2023-04-12 English
Compliance ceritifcate under Reg. 40 (9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended at March 31, 2023.
Regulatory Filings
2023-04-07 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2023. It is a compliance certificate from the Registrar and Share Transfer Agent confirming dematerialization and listing of securities. The document is short (2369 characters) and primarily serves as a regulatory compliance certificate rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or detailed report content. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory compliance document and not a full report or announcement of a report.
2023-04-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.